Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Published byLoraine Campbell Modified over 6 years ago

Similar presentations

Presentation on theme: "Fig. 4. Antitumor efficacy of ERY974 against various cancer types."— Presentation transcript:

1 Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Antitumor efficacy of ERY974 against various cancer types. (A) GPC3 expression in various cancer cell lines determined by quantitative flow cytometry. (B) IHC results of GPC3 staining in xenograft tissues of indicated cancer cell lines. H-scores in the cytoplasm are indicated in parentheses. Images were taken using a 20× objective. (C) Antitumor efficacy of ERY974 against various xenograft tumors in NOD-SCID mice inoculated with human T cells. Mean tumor volume values are shown + SD (n = 5). *P < 0.05 between vehicle and ERY974 group by Wilcoxon test. Arrows indicate timing of ERY974 administration. (D) Antitumor efficacy of ERY974 against large tumors. When the mean volume of implanted KYSE70 tumors reached more than 600 mm3, vehicle or ERY974 (1 mg/kg) was administered 3 to 5 hours after the T cell injection. Mean tumor volumes in each group are shown + SD (n = 4). Images represent tumor burden over time in one representative animal dosed with ERY974 on day 29. (E) Antitumor efficacy of ERY974 against GPC3-negative cell xenograft tumors. Mean values for tumor volume in each group are shown + SD (n = 5). Takahiro Ishiguro et al., Sci Transl Med 2017;9:eaal4291 Published by AAAS

Download ppt "Fig. 4. Antitumor efficacy of ERY974 against various cancer types."

Similar presentations

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Supplementary Figure S13

Supplementary Figure S13
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
In vivo prophylactic and therapeutic efficacy of C12G6 in mice

In vivo prophylactic and therapeutic efficacy of C12G6 in mice
Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. In vivo suppression of MM by CMLD
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 1 DMF promotes viral infection.

Fig. 1 DMF promotes viral infection.
Intravenous delivery of reovirus to primary and secondary brain tumors

Intravenous delivery of reovirus to primary and secondary brain tumors
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 5 A competent Fc is required for the antitumor immune response.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Similar presentations

Ads by Google